BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 19852727)

  • 1. Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
    Wendt MK; Allington TM; Schiemann WP
    Future Oncol; 2009 Oct; 5(8):1145-68. PubMed ID: 19852727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells.
    Taylor MA; Parvani JG; Schiemann WP
    J Mammary Gland Biol Neoplasia; 2010 Jun; 15(2):169-90. PubMed ID: 20467795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition in hepatocellular carcinoma.
    van Zijl F; Zulehner G; Petz M; Schneller D; Kornauth C; Hau M; Machat G; Grubinger M; Huber H; Mikulits W
    Future Oncol; 2009 Oct; 5(8):1169-79. PubMed ID: 19852728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial-mesenchymal transition in development and cancer.
    Micalizzi DS; Ford HL
    Future Oncol; 2009 Oct; 5(8):1129-43. PubMed ID: 19852726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism.
    Lee YH; Albig AR; Regner M; Schiemann BJ; Schiemann WP
    Carcinogenesis; 2008 Dec; 29(12):2243-51. PubMed ID: 18713838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis.
    Rajasekaran SA; Huynh TP; Wolle DG; Espineda CE; Inge LJ; Skay A; Lassman C; Nicholas SB; Harper JF; Reeves AE; Ahmed MM; Leatherman JM; Mullin JM; Rajasekaran AK
    Mol Cancer Ther; 2010 Jun; 9(6):1515-24. PubMed ID: 20501797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression.
    Wendt MK; Tian M; Schiemann WP
    Cell Tissue Res; 2012 Jan; 347(1):85-101. PubMed ID: 21691718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β signaling and epithelial-mesenchymal transition in cancer progression.
    Katsuno Y; Lamouille S; Derynck R
    Curr Opin Oncol; 2013 Jan; 25(1):76-84. PubMed ID: 23197193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
    Galliher AJ; Schiemann WP
    Breast Cancer Res; 2006; 8(4):R42. PubMed ID: 16859511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies.
    Lenferink AE; Cantin C; Nantel A; Wang E; Durocher Y; Banville M; Paul-Roc B; Marcil A; Wilson MR; O'Connor-McCourt MD
    Oncogene; 2010 Feb; 29(6):831-44. PubMed ID: 19935703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.
    Han G; Lu SL; Li AG; He W; Corless CL; Kulesz-Martin M; Wang XJ
    J Clin Invest; 2005 Jul; 115(7):1714-23. PubMed ID: 15937546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta1 causes epithelial-mesenchymal transition in HaCaT derivatives, but induces expression of COX-2 and migration only in benign, not in malignant keratinocytes.
    Räsänen K; Vaheri A
    J Dermatol Sci; 2010 May; 58(2):97-104. PubMed ID: 20399617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of the TGF-β Paradox to EMT-MET programs.
    Morrison CD; Parvani JG; Schiemann WP
    Cancer Lett; 2013 Nov; 341(1):30-40. PubMed ID: 23474494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.
    Neil JR; Johnson KM; Nemenoff RA; Schiemann WP
    Carcinogenesis; 2008 Nov; 29(11):2227-35. PubMed ID: 18725385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
    Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
    Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
    Micalizzi DS; Christensen KL; Jedlicka P; Coletta RD; Barón AE; Harrell JC; Horwitz KB; Billheimer D; Heichman KA; Welm AL; Schiemann WP; Ford HL
    J Clin Invest; 2009 Sep; 119(9):2678-90. PubMed ID: 19726885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial-mesenchymal transition in mouse mammary tumorigenesis.
    Radaelli E; Damonte P; Cardiff RD
    Future Oncol; 2009 Oct; 5(8):1113-27. PubMed ID: 19852725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta-induced epithelial to mesenchymal transition.
    Xu J; Lamouille S; Derynck R
    Cell Res; 2009 Feb; 19(2):156-72. PubMed ID: 19153598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
    Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
    Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of particulate matter and substrate stiffness on epithelial-to-mesenchymal transition.
    Barker TH; Dysart MM; Brown AC; Douglas AM; Fiore VF; Russell AG;
    Res Rep Health Eff Inst; 2014 Nov; (182):3-41. PubMed ID: 25669020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.